Cyclo(RGDyC)

• CAT Number: I040657
• CAS Number: 1206475-79-7
• Molecular Formula: C24H34N8O8S
• Molecular Weight: 594.64
• Purity: ≥95%
• Synonyms: 2-[(2S,5R,8R,11S)-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-8-(sulfanylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
• InChI: InChI=1S/C24H34N8O8S/c25-24(26)27-7-1-2-14-20(37)28-10-18(34)29-16(9-19(35)36)22(39)31-15(8-12-3-5-13(33)6-4-12)21(38)32-17(11-41)23(40)30-14/h3-6,14-17,33,41H,1-2,7-11H2,(H,28,37)(H,29,34)(H,30,40)(H,31,39)(H,32,38)(H,35,36)(H4,25,26,27)/t14-,15+,16-,17-/m0/s1
• InChIKey: MOAUBYMRAXXSJA-YVSFHVDLSA-N
• SMILES: C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CS)CC2=CC=C(C=C2)O)CC(=O)O

Cyclo(RGDyC) (Cat No.: I040657) is a cyclic pentapeptide containing the arginine-glycine-aspartic acid (RGD) motif, which specifically binds to integrin receptors, particularly αvβ3 integrins. These receptors are overexpressed in tumor vasculature and activated endothelial cells, making Cyclo(RGDyC) a valuable tool in cancer imaging, targeted drug delivery, and anti-angiogenic therapy. The cyclic structure enhances its binding affinity and metabolic stability. Cyclo(RGDyC) is often conjugated to imaging agents, nanoparticles, or therapeutics for precise targeting of tumor cells and neovasculature in preclinical and clinical research.

Reference

[1]. Lu Y, et al. Aqueous synthesized near-infrared-emitting quantum dots for RGD-based in vivo active tumour targeting. Nanotechnology. 2013 Apr 5;24(13):135101.
[Content Brief]

[2]. Tang M, et al. Photostable and Biocompatible Fluorescent Silicon Nanoparticles-Based Theranostic Probes for Simultaneous Imaging and Treatment of Ocular Neovascularization. Anal Chem. 2018 Jul 3;90(13):8188-8195.
[Content Brief]